Maui Derm NPPA Logo Web

Maui Derm NP+PA is a series of CME meetings designed exclusively for Nurse Practitioners and Physician Assistants practicing in dermatology.

Based on an unmet need for excellence in dermatology education for dermatologic Nurse Practitioners and Physician Assistants, a series of three meetings called Maui Derm NP+PA were specifically designed to meet this unfulfilled need.

The scientific advisory board (listed below) for Maui Derm NP+PA represent the key educators and society leadership in both NP and PA societies. The curriculum developed for the Maui Derm NP+PA meetings is based on a recent paper published by one or our board members on the educational needs of NPs (see attached).

Because our meetings are “NP and PA dermatology specific”, in order to attend Maui Derm NP+PA registrants are required to be members of their national, regional or local societies or have a dermatologist verify that their practice is specific to dermatology.

The faculty is comprised of the highest-level dermatology KOLs who were selected for teaching excellence. Each meeting covers important topics in dermatology with the new information formatted to reinforce key concepts while avoiding redundancy between the three meetings.

Mission Statement

To increase Nurse Practitioners (NPs) and Physician Assistants (PAs) knowledge in areas of medical and cosmetic dermatology in order to enable the Nurse Practitioners (NPs) and Physician Assistants (PAs) to provide better care for their patients.

Program Rationale

The Dermatology landscape is ever changing. There have been significant advances with regards to the diagnosis, management and treatment of both medical and cosmetic dermatologic conditions. NPs and PAs require targeted education regarding the proper management of these conditions.

Target Audience

This educational activity is designed for NPs and PAs who specialize in dermatology.

Overall Learning Objectives

    1. Review the pathogenesis of various dermatological conditions such as infectious diseases, nail disorders, psoriasis, psoriatic arthritis, acne vulgaris, rosacea, hidradenitis, contact dermatitis, atopic dermatitis, eczema, actinic keratoses, melanoma and non-melanoma skin cancer, pediatric skin disorders, connective tissue disorders, granulomatous disorders of the skin, autoimmune blistering diseases, leg ulcers, oral lesions and life-threatening dermatoses such as TEN in order to accurately diagnose and improve upon the management of these conditions in patients
    2. Cite the mechanisms of action of various drugs, including topical and systemic therapies, as well as immunomodulatory agents that are commonly prescribed by the nurse practitioner and physician assistant practicing in dermatology and identify patients in your practice for whom these therapies may be appropriate
    3. Define appropriate outcome measures for the optimal follow-up of patients with dermatologic diseases as well as those receiving surgical and cosmetic procedures in order to set realistic expectations and maximize therapeutic outcomes
    4. Describe potential adverse events, safety, tolerance and resistance issues that may be related to the use of various drugs and therapies prescribed by clinicians in dermatology as well as therapeutic modalities including: topical and systemic corticosteroids, newer biologic agents, including TNF antagonists, T-cell targeted therapies, anti-IL-12/23 therapies, IL-23 & IL-17 antibodies, systemic and topical PDE4 inhibitors, JAK inhibitors, anti-IgE and anti-IL 4 receptor, anti B-cell therapies, retinoids, methotrexate, cyclosporine, systemic and topical acne/rosacea/hidradenitis suppuritiva therapies, oral and topical antibiotics, antifungals, anti-virals, antihistamines, calcineurin inhibitors, topical skin lightening agents, sunscreens, topical and systemic retinoids, 5-fluorouracil, imiquimod,  ingenol mebutate, diclofenac, hedgehog pathway inhibitors, BRAF/MEK inhibitors, CTLA-4 and PD-1 inhibitors, botulinum toxins, dermal filler agents including hyaluronic acid, collagen, polylactic acid, hydroxyappetite based fillers, and photodynamic therapy, and implement appropriate management strategies in order to reduce these adverse effects and optimize patient outcomes
    5. Assess the data around emerging and novel therapeutics for a variety of dermatologic diseases and develop treatment algorithms and management strategies for the optimal use of these therapies
    6. Discuss the importance of clinician/patient communication regarding benefit versus risk, patient satisfaction, and adherence when selecting therapies for patients

Enduring Education


Based upon the evidence-based content delivered at the Maui Derm NP+PA 2013 conference, the educational eNewsletters will cover the various topics delivered from the meeting. These quarterly eNewsletters will be delivered electronically via an “opt-in” process to the dermatology community. The e-newsletters will include key talking points from the presentations, challenging cases including both diagnostic and management issues, embedded videos and podcasts, and downloadable slides. Topics to be included are:

    • Psoriasis
    • Acne/Rosacea
    • Toxins/Fillers
    • Pediatric Dermatology
    • Cutaneous Oncology & Pigmented Lesions
    • Cutaneous Surgery
    • Infectious Disease
    • New Drugs
    • Cutaneous Immunology
    • Oral and Genital Lesions
    • Aging Skin & Cosmeceuticals
    • Connective Tissue Diseases

Therapeutic Forum

The Maui Derm NP+PA Therapeutic Forum is an online forum that discusses hot topics and challenging cases and allows for participants to view pictures and videos that accompany the case studies. Faculty will be available to discuss the cases and viewers will have an opportunity to pose challenging questions to the faculty. All topics and case studies will be based upon the evidence-based medicine discussed at the live meeting. Online forums allow us to assess knowledge gaps and practice patterns and provide a means for future needs assessments.